{"status": "ok", "totalResults": 5, "articles": [{"source": {"id": null, "name": "[Removed]"}, "author": null, "title": "[Removed]", "description": "[Removed]", "url": "https://removed.com", "urlToImage": null, "publishedAt": "1970-01-01T00:00:00Z", "content": "[Removed]"}, {"source": {"id": null, "name": "Financial Times"}, "author": "Tom Wilson", "title": "Who are Anglo American's possible suitors? - Financial Times", "description": "The UK-listed miner has rejected an approach from BHP, but other bidders could emerge", "url": "https://www.ft.com/content/884d2bb0-57e8-4d82-b4b3-db314038e2a9", "urlToImage": "https://www.ft.com/__origami/service/image/v2/images/raw/https%3A%2F%2Fwww.ft.com%2F__origami%2Fservice%2Fimage%2Fv2%2Fimages%2Fraw%2Fhttps%253A%252F%252Fd1e00ek4ebabms.cloudfront.net%252Fproduction%252F66d10d29-e409-4ba6-95b4-eeb1c6882a73.jpg%3Fsource%3Dnext-article%26fit%3Dscale-down%26quality%3Dhighest%26width%3D700%26dpr%3D1?source=next-opengraph&fit=scale-down&width=900", "publishedAt": "2024-04-29T17:58:34Z", "content": "BHPs unsolicited \u00a331bn takeover approach for Anglo American has shaken up the mining industry, provoking speculation that the storied company is ripe to be sold or broken up.\r\nAnglo rejected the prel\u2026 [+5907 chars]"}, {"source": {"id": null, "name": "Futurism"}, "author": "Noor Al-Sibai", "title": "AI Startups Are Suddenly In Huge Trouble - Futurism", "description": "As the speculative bubble surrounding AI begins to burst, the people behind them \u2014 and their financiers \u2014 are starting to feel the burn.", "url": "https://futurism.com/the-byte/ai-startups-money-trouble", "urlToImage": "https://wp-assets.futurism.com/2024/04/ai-startups-money-trouble.jpg", "publishedAt": "2024-04-29T16:38:09Z", "content": "\"You can already see the writing on the wall.\"\r\nBubble Bubble\r\nAs the speculative bubble surrounding AI shows signs of bursting, the startups that banked on the tech and their financiers are starting\u2026 [+2464 chars]"}, {"source": {"id": null, "name": "[Removed]"}, "author": null, "title": "[Removed]", "description": "[Removed]", "url": "https://removed.com", "urlToImage": null, "publishedAt": "1970-01-01T00:00:00Z", "content": "[Removed]"}, {"source": {"id": null, "name": "Astrazeneca.com"}, "author": null, "title": "Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low metastatic breast cancer following one or more lines of endocrine therapy in DESTINY-Breast06 Phase III trial - AstraZeneca", "description": "", "url": "https://www.astrazeneca.com/media-centre/press-releases/2024/enhertu-improved-pfs-in-her2-low-and-ultralow.html", "urlToImage": "", "publishedAt": "2024-04-29T01:30:00Z", "content": "Positive high-level results from the DESTINY-Breast06 Phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in pr\u2026 [+12518 chars]"}]}